Foghorn Therapeutics 1 article

Within biopharma, Foghorn Therapeutics operates as a biopharmaceutical company linking chromatin regulatory therapeutics with Gene Traffic Control platform. For Foghorn Therapeutics, BAF chromatin remodeling complex targeting and SMARCA2 selective ATPase inhibition broaden the research base, while ARID1B targeted protein degradation adds a specific target, pathway, delivery method or disease context. GenoMethods separates the corporate identity of Foghorn Therapeutics from its drug-level entities; degrader antibody conjugate payloads remains useful for company-level matching.